Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 8

1.

Effectiveness and safety of dual therapy with rilpivirine and boosted darunavir in treatment-experienced patients with advanced HIV infection: a preliminary 24 week analysis (RIDAR study).

Pasquau J, de Jesus SE, Arazo P, Crusells MJ, Ríos MJ, Lozano F, de la Torre J, Galindo MJ, Carmena J, Santos J, Tornero C, Verdejo G, Samperiz G, Palacios Z, Hidalgo-Tenorio C; RIDAR Study Group.

BMC Infect Dis. 2019 Feb 28;19(1):207. doi: 10.1186/s12879-019-3817-6.

2.

Interferon-free therapy for treating hepatitis C virus in difficult-to-treat HIV-coinfected patients.

Mínguez C, García-Deltoro M, Flores J, Galindo MJ, Montero M, Reus S, Carmena J, Masiá M, Amador C, Ortega E; on the behalf of the COINFECOVA-2 study group.

AIDS. 2018 Jan 28;32(3):337-346. doi: 10.1097/QAD.0000000000001699.

PMID:
29309345
3.

Telaprevir or boceprevir in HIV/HCV-1 co-infected patients in a real-life setting. Interim analysis (24 weeks). COINFECOVA-SEICV study.

Minguez C, Ortega E, Flores J, Carmena J, Masiá M, Montero M, Reus S, Tornero C, Galindo MJ, Garcia-Deltoro M, Amador C, Cuadrado JM, Usó J, López-Aldeguer J.

J Int AIDS Soc. 2014 Nov 2;17(4 Suppl 3):19634. doi: 10.7448/IAS.17.4.19634. eCollection 2014.

4.

Switching to raltegravir in virologically suppressed in HIV-1-infected patients: a retrospective, multicenter, descriptive study.

Podzamczer D, Martínez E, Domingo P, Ferrer E, Viciana P, Curto J, Pérez-Elías MJ, Ocampo A, Santos I, Knobel H, Estrada V, Negredo E, Segura F, Portilla J, Ribera E, Galindo J, Antela A, Carmena J, Castaño M, The Toral Study Group.

Curr HIV Res. 2012 Dec;10(8):673-8.

PMID:
23061598
5.

The future of antiretroviral therapy: challenges and needs.

Moreno S, López Aldeguer J, Arribas JR, Domingo P, Iribarren JA, Ribera E, Rivero A, Pulido F; HIV 2020 Project.

J Antimicrob Chemother. 2010 May;65(5):827-35. doi: 10.1093/jac/dkq061. Epub 2010 Mar 12. Review.

PMID:
20228080
6.

Prevalence and impact of body physical changes in HIV patients treated with highly active antiretroviral therapy: results from a study on patient and physician perceptions.

Cabrero E, Griffa L, Burgos A; HIV Body Physical Changes Study Group.

AIDS Patient Care STDS. 2010 Jan;24(1):5-13. doi: 10.1089/apc.2009.0191.

PMID:
20095903
7.

Tigecycline: a new treatment choice against Acinetobacter baumannii.

Bosó-Ribelles V, Romá-Sánchez E, Carmena J, Cáceres C, Bautista D.

Recent Pat Antiinfect Drug Discov. 2008 Jun;3(2):117-22. Review.

PMID:
18673124
8.

Adherence, quality of life, and general satisfaction with co-formulated zidovudine, lamivudine, and abacavir on antiretroviral-experienced patients.

Clotet B, Carmena J, Pulido F, Luque I, Rodriguez-Alcántara F; COL30494 Cohort Study Members.

HIV Clin Trials. 2004 Jan-Feb;5(1):33-9.

PMID:
15002085

Supplemental Content

Loading ...
Support Center